A targetable SWI/SNF dependency sustains survival in pediatric B-ALL

Pediatric B-cell acute lymphoblastic leukemia (B-ALL) remains a major clinical challenge driven by molecular heterogeneity and therapeutic resistance. While the SWI/SNF chromatin-remodeling complex is a recognized dependency in myeloid and T-cell leukemias, its role in B-ALL remains poorly defined. Here, we identify a conserved requirement for the SWI/SNF ATPases SMARCA4 and SMARCA2 across diverse B-ALL genetic subtypes. SMARCA4 expression correlates with inferior overall survival in the pediatric B-ALL TARGET cohort. Using a panel of B-ALL models representing ETV6-RUNX1, BCR-ABL1, and KMT2A-rearranged subtypes, we show that dual SMARCA2/4 inhibition, using the ATPase inhibitor BRM014 or the PROTAC degrader ACBI1, induces profound loss of viability. This vulnerability is characterized by G0/G1 cell cycle arrest and a robust apoptotic response. Mechanistically, comparative RNA sequencing identified a high-confidence 26-gene "identity core" consistently downregulated upon SWI/SNF disruption with BRM014. This program integrates lymphocyte activation, cytokine signaling, and trafficking modules, including the key niche-interaction receptor CXCR4, and is accompanied by depletion of MYC and E2F transcriptional programs. Finally, BRM014 demonstrated significant growth-inhibitory activity in vivo in an REH xenograft model, with a significant delay in disease progression during the observation window. These findings establish the SWI/SNF complex as a conserved survival dependency in the tested B-ALL models and provide a rationale for targeting SMARCA2/4 to inhibit intrinsic growth in B-ALL.

Authors

Institutions

Publication Details

Journal
Experimental Hematology and Oncology
Published
2026-11-18
DOI
https://doi.org/10.1186/s40164-026-00847-4
Primary Topic
Chromatin Remodeling and Cancer
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A targetable SWI/SNF dependency sustains survival in pediatric B-ALL

Pedro P. Medina, Juan de los Santos-Jiménez, Sergio Castro‐Gonzalez, Fernando Montenegro-Elvira
4 links
Experimental Hematology and Oncology
Chromatin Remodeling and Cancer
article

A targetable SWI/SNF dependency sustains survival in pediatric B-ALL

Pedro P. Medina, Juan de los Santos-Jiménez, Sergio Castro‐Gonzalez, Fernando Montenegro-Elvira
article en

Abstract

Pediatric B-cell acute lymphoblastic leukemia (B-ALL) remains a major clinical challenge driven by molecular heterogeneity and therapeutic resistance. While the SWI/SNF chromatin-remodeling complex is a recognized dependency in myeloid and T-cell leukemias, its role in B-ALL remains poorly defined. Here, we identify a conserved requirement for the SWI/SNF ATPases SMARCA4 and SMARCA2 across diverse B-ALL genetic subtypes. SMARCA4 expression correlates with inferior overall survival in the pediatric B-ALL TARGET cohort. Using a panel of B-ALL models representing ETV6-RUNX1, BCR-ABL1, and KMT2A-rearranged subtypes, we show that dual SMARCA2/4 inhibition, using the ATPase inhibitor BRM014 or the PROTAC degrader ACBI1, induces profound loss of viability. This vulnerability is characterized by G0/G1 cell cycle arrest and a robust apoptotic response. Mechanistically, comparative RNA sequencing identified a high-confidence 26-gene "identity core" consistently downregulated upon SWI/SNF disruption with BRM014. This program integrates lymphocyte activation, cytokine signaling, and trafficking modules, including the key niche-interaction receptor CXCR4, and is accompanied by depletion of MYC and E2F transcriptional programs. Finally, BRM014 demonstrated significant growth-inhibitory activity in vivo in an REH xenograft model, with a significant delay in disease progression during the observation window. These findings establish the SWI/SNF complex as a conserved survival dependency in the tested B-ALL models and provide a rationale for targeting SMARCA2/4 to inhibit intrinsic growth in B-ALL.

Experimental Hematology and OncologyVol. 15(1)
Universidad de Granada (ES), Instituto de Investigación Biosanitaria de Granada (ES), Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (ES)
Junta de Andalucía, European Regional Development Fund, Agencia Estatal de Investigación, European Social Fund
Good health and well-being
Chromatin Remodeling and Cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon